<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>polatuzumab vedotin &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/polatuzumab-vedotin/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 09 Oct 2026 02:10:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>polatuzumab vedotin &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Rare Thyroid Lymphoma Returns Six Years Later — and a New Drug Regimen Beats It Back</title>
		<link>https://bioengineer.org/rare-thyroid-lymphoma-returns-six-years-later-and-a-new-drug-regimen-beats-it-back/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 02:10:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Annals of Hematology]]></category>
		<category><![CDATA[chemoimmunotherapy]]></category>
		<category><![CDATA[diffuse large B-cell lymphoma]]></category>
		<category><![CDATA[DLBCL]]></category>
		<category><![CDATA[extranodal lymphoma]]></category>
		<category><![CDATA[non-Hodgkin lymphoma]]></category>
		<category><![CDATA[polatuzumab vedotin]]></category>
		<category><![CDATA[primary thyroid lymphoma]]></category>
		<category><![CDATA[R-CHOP]]></category>
		<category><![CDATA[relapse]]></category>
		<category><![CDATA[rituximab]]></category>
		<category><![CDATA[Thyroid cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=409162</guid>

					<description><![CDATA[A new case report in the Annals of Hematology describes a woman whose rare primary thyroid diffuse large B-cell lymphoma relapsed six years later in the opposite thyroid lobe and achieved complete remission again after off-label polatuzumab-based therapy.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">409162</post-id>	</item>
	</channel>
</rss>
